Hemrajani Rekha 4

What Happened
Rekha Hemrajani (listed as Hemrajani Rekha), a director of BioAge Labs, Inc. (BIOA), received a derivative award for 22,000 shares on 2026-06-10. The transaction is reported as an award/acquisition (code A) with a reported price of $0.00 and total reported cash value of $0. This appears to be a compensatory option-style award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-10; filing date (Form 4): 2026-06-12 (filed 2 days after the transaction).
• Award: 22,000 shares; reported price: $0.00; total reported cash value: $0.
• Shares owned after transaction: Not specified in the filing.
• Footnote (F1): The entire option award vests on the earlier of (i) the date of the next annual meeting of stockholders or (ii) the one-year anniversary of the grant date, subject to the reporting person’s continued service.
• Timeliness: Filing appears timely (within the typical 2-business-day window).

Context
This is a grant of a derivative/option-style award used for director compensation. Such awards do not represent an open-market purchase (a bullish signal) or a sale; they are routine compensation and should be interpreted accordingly. The award vests in full within a year (or at the next annual meeting) if the director remains in service.